EpiVacCorona Vaccine Description
EpiVacCorona is a coronavirus vaccine developed by the Vektor State Research Center of Virology and Biotechnology in Russia.
Russian researchers have succeeded in creating vaccines both on the basis of widely used recombinant viral vectors of influenza, measles and vesicular stomatitis, and on the basis of promising technologies for synthetic vaccines: mRNA vaccines, peptide vaccines, and subunit vaccines. For the design of vaccines, modern bio-information systems were used, and the design and refinement to finished prototypes were carried out using advanced developments, including in the field of reverse genetics.
As of March 16, 2020, scientists of the State Research Center of VB "Vector" of Rospotrebnadzor began studies of immunogenicity in sensitive laboratory animals, including lower primates of all developed vaccine prototypes. Within the framework of the research, the most promising and safe prototypes will be determined that ensure the formation of both cellular and humoral immune responses.
Scientists expect that the introduction of the vaccine will be possible in the fourth quarter of 2020.
Federal Budgetary Institution of Science The State Research Center for Virology and Biotechnology "Vector" is one of the largest scientific virological and biotechnological centers in Russia. The Center was organized in 1974. It includes a branch - the Institute of Medical Biotechnology, located in Berdsk, Novosibirsk Region.
EpiVacCorona Vaccine Indication
EpiVacCorona Vaccine is indicated to prevent COVID-19 a disease caused by SARS-Cov-2. The composition, dose, method of administration of the future vaccine will be determined.
EpiVacCorona Vaccine News
August 6, 2020 - Another 86 volunteers will be inoculated with the vaccine against the novel coronavirus developed by the Vektor State Research Center of Virology and Biotechnology during the second stage of clinical trials, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.
August 5, 2020 - EpiVacCorona is being developed by VECTOR, taking into account all mandatory requirements and regulatory recommendations provided for by the Russian Federation's legislation, the watchdog said. According to Rospotrebnadzor, the research protocols that comply with the Russian and world experience and strictly adhere to the research rules indicate the drug's quality.
August 2, 2020 - "All vaccinated volunteers are in good health. No complications after the inoculation with the EpiVacCorona vaccine against the coronavirus have been recorded," the statement said.
July 30, 2020 - The Russian Vektor State Research Center will monitor volunteers testing a vaccine against COVID-19 from three to six weeks, the official government site stop coronavirus.rf's Telegram channel, citing Russia's Rospotrebnadzor consumer watchdog.
July 28, 2020 - Center “Vector” began testing the Russian peptide vaccine against COVID-19 disease.
March 20, 2020 - In Russia, for the prevention and control of the COVID-19 epidemic in the State Research Center of VB "Vector" of Rospotrebnadzor, vaccine prototypes based on six different technological platforms were developed in the shortest possible time.
EpiVacCorona Vaccine Clinical Trials
According to information in registry Russian clinical trials, the combined first and second phase trials of the EpiVacCorona vaccine were registered on July 24, 2020. Simple-blind, placebo-controlled, randomized trials will involve 100 volunteers aged 18 to 60 years.
The Center received approval to conduct a clinical trial of the EpiVacCorona vaccine candidate on July 27, 2020. Five people aged 18 to 30 take part in the first stage of the test. They are vaccinated in turn, with an interval of 72 hours.